WO2017029298A1 - Composition antivirale topique - Google Patents
Composition antivirale topique Download PDFInfo
- Publication number
- WO2017029298A1 WO2017029298A1 PCT/EP2016/069450 EP2016069450W WO2017029298A1 WO 2017029298 A1 WO2017029298 A1 WO 2017029298A1 EP 2016069450 W EP2016069450 W EP 2016069450W WO 2017029298 A1 WO2017029298 A1 WO 2017029298A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oil
- weight
- total formulation
- pharmaceutical composition
- topical pharmaceutical
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 202
- 230000000840 anti-viral effect Effects 0.000 title claims abstract description 26
- 230000000699 topical effect Effects 0.000 title abstract description 14
- 239000003921 oil Substances 0.000 claims abstract description 80
- 239000004480 active ingredient Substances 0.000 claims abstract description 33
- 239000002253 acid Substances 0.000 claims abstract description 13
- 238000009472 formulation Methods 0.000 claims description 160
- 235000019198 oils Nutrition 0.000 claims description 78
- 239000012049 topical pharmaceutical composition Substances 0.000 claims description 57
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 54
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical group OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 45
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 40
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 claims description 39
- 229960001179 penciclovir Drugs 0.000 claims description 36
- 229960004150 aciclovir Drugs 0.000 claims description 35
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 33
- 235000004866 D-panthenol Nutrition 0.000 claims description 30
- 239000011703 D-panthenol Substances 0.000 claims description 30
- 229960003949 dexpanthenol Drugs 0.000 claims description 30
- 235000010654 Melissa officinalis Nutrition 0.000 claims description 28
- 244000062730 Melissa officinalis Species 0.000 claims description 28
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 27
- 229960000458 allantoin Drugs 0.000 claims description 27
- 239000010648 geranium oil Substances 0.000 claims description 27
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 claims description 27
- 239000010668 rosemary oil Substances 0.000 claims description 26
- 229940058206 rosemary oil Drugs 0.000 claims description 26
- 235000019717 geranium oil Nutrition 0.000 claims description 25
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 24
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 24
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims description 24
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 24
- 235000019477 peppermint oil Nutrition 0.000 claims description 24
- 229940101267 panthenol Drugs 0.000 claims description 15
- 235000020957 pantothenol Nutrition 0.000 claims description 15
- 239000011619 pantothenol Substances 0.000 claims description 15
- 208000004898 Herpes Labialis Diseases 0.000 claims description 12
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims description 12
- 229960000541 cetyl alcohol Drugs 0.000 claims description 12
- 229940057995 liquid paraffin Drugs 0.000 claims description 12
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 12
- 239000012188 paraffin wax Substances 0.000 claims description 12
- 229950011392 sorbitan stearate Drugs 0.000 claims description 12
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 11
- 229960005323 phenoxyethanol Drugs 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 10
- 208000029433 Herpesviridae infectious disease Diseases 0.000 claims description 10
- 229960003511 macrogol Drugs 0.000 claims description 10
- 241000700605 Viruses Species 0.000 claims description 9
- -1 black Substances 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 241001529453 unidentified herpesvirus Species 0.000 claims description 8
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 7
- 230000000306 recurrent effect Effects 0.000 claims description 7
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical group C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims description 6
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 5
- 230000007420 reactivation Effects 0.000 claims description 5
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 4
- 241000701022 Cytomegalovirus Species 0.000 claims description 4
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims description 4
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 4
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 4
- 230000000845 anti-microbial effect Effects 0.000 claims description 4
- 239000010628 chamomile oil Substances 0.000 claims description 4
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 claims description 4
- 239000010642 eucalyptus oil Substances 0.000 claims description 4
- 229940044949 eucalyptus oil Drugs 0.000 claims description 4
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 claims description 4
- 239000010466 nut oil Substances 0.000 claims description 4
- 239000010502 orange oil Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 206010019972 Herpes viral infections Diseases 0.000 claims description 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 3
- 229940116269 uric acid Drugs 0.000 claims description 3
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 claims description 2
- 235000006667 Aleurites moluccana Nutrition 0.000 claims description 2
- 244000136475 Aleurites moluccana Species 0.000 claims description 2
- 235000019489 Almond oil Nutrition 0.000 claims description 2
- 235000003880 Calendula Nutrition 0.000 claims description 2
- 240000001432 Calendula officinalis Species 0.000 claims description 2
- 235000002566 Capsicum Nutrition 0.000 claims description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 2
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims description 2
- 235000005979 Citrus limon Nutrition 0.000 claims description 2
- 244000131522 Citrus pyriformis Species 0.000 claims description 2
- 235000005976 Citrus sinensis Nutrition 0.000 claims description 2
- 240000002319 Citrus sinensis Species 0.000 claims description 2
- 241000675108 Citrus tangerina Species 0.000 claims description 2
- 240000002943 Elettaria cardamomum Species 0.000 claims description 2
- 240000006927 Foeniculum vulgare Species 0.000 claims description 2
- 235000002782 Foeniculum vulgare var dulce Nutrition 0.000 claims description 2
- 235000019487 Hazelnut oil Nutrition 0.000 claims description 2
- 241000701041 Human betaherpesvirus 7 Species 0.000 claims description 2
- 235000017309 Hypericum perforatum Nutrition 0.000 claims description 2
- 244000141009 Hypericum perforatum Species 0.000 claims description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 2
- 229930010555 Inosine Natural products 0.000 claims description 2
- 235000017858 Laurus nobilis Nutrition 0.000 claims description 2
- 244000147568 Laurus nobilis Species 0.000 claims description 2
- 235000019501 Lemon oil Nutrition 0.000 claims description 2
- 235000012854 Litsea cubeba Nutrition 0.000 claims description 2
- 240000002262 Litsea cubeba Species 0.000 claims description 2
- 235000018330 Macadamia integrifolia Nutrition 0.000 claims description 2
- 235000003800 Macadamia tetraphylla Nutrition 0.000 claims description 2
- 240000000912 Macadamia tetraphylla Species 0.000 claims description 2
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims description 2
- 244000042664 Matricaria chamomilla Species 0.000 claims description 2
- 102000016943 Muramidase Human genes 0.000 claims description 2
- 108010014251 Muramidase Proteins 0.000 claims description 2
- 240000005125 Myrtus communis Species 0.000 claims description 2
- 235000013418 Myrtus communis Nutrition 0.000 claims description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 2
- 241000772415 Neovison vison Species 0.000 claims description 2
- 235000010679 Nepeta cataria Nutrition 0.000 claims description 2
- 240000009215 Nepeta cataria Species 0.000 claims description 2
- 235000019502 Orange oil Nutrition 0.000 claims description 2
- 240000000783 Origanum majorana Species 0.000 claims description 2
- 235000006297 Origanum majorana Nutrition 0.000 claims description 2
- 235000019483 Peanut oil Nutrition 0.000 claims description 2
- 235000017927 Pelargonium graveolens Nutrition 0.000 claims description 2
- 244000270673 Pelargonium graveolens Species 0.000 claims description 2
- 239000006002 Pepper Substances 0.000 claims description 2
- 235000016761 Piper aduncum Nutrition 0.000 claims description 2
- 240000003889 Piper guineense Species 0.000 claims description 2
- 235000017804 Piper guineense Nutrition 0.000 claims description 2
- 235000008184 Piper nigrum Nutrition 0.000 claims description 2
- 241000494043 Ravensara Species 0.000 claims description 2
- 241000220317 Rosa Species 0.000 claims description 2
- 235000019486 Sunflower oil Nutrition 0.000 claims description 2
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims description 2
- 244000223014 Syzygium aromaticum Species 0.000 claims description 2
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 claims description 2
- 235000019498 Walnut oil Nutrition 0.000 claims description 2
- 239000001269 achillea millefolium l. oil Substances 0.000 claims description 2
- 239000008168 almond oil Substances 0.000 claims description 2
- 239000010617 anise oil Substances 0.000 claims description 2
- 235000021302 avocado oil Nutrition 0.000 claims description 2
- 239000008163 avocado oil Substances 0.000 claims description 2
- 239000010480 babassu oil Substances 0.000 claims description 2
- 239000010619 basil oil Substances 0.000 claims description 2
- 229940018006 basil oil Drugs 0.000 claims description 2
- 239000001491 betula lenta l. bark oil Substances 0.000 claims description 2
- 239000001342 boswellia carteri birdw. oil Substances 0.000 claims description 2
- 239000010684 cajeput oil Substances 0.000 claims description 2
- 239000010495 camellia oil Substances 0.000 claims description 2
- 239000010624 camphor oil Substances 0.000 claims description 2
- 229960000411 camphor oil Drugs 0.000 claims description 2
- 235000019519 canola oil Nutrition 0.000 claims description 2
- 239000000828 canola oil Substances 0.000 claims description 2
- 235000005300 cardamomo Nutrition 0.000 claims description 2
- 235000019480 chamomile oil Nutrition 0.000 claims description 2
- 235000017803 cinnamon Nutrition 0.000 claims description 2
- 239000010632 citronella oil Substances 0.000 claims description 2
- 239000001279 citrus aurantifolia swingle expressed oil Substances 0.000 claims description 2
- 239000001111 citrus aurantium l. leaf oil Substances 0.000 claims description 2
- 239000001926 citrus aurantium l. subsp. bergamia wright et arn. oil Substances 0.000 claims description 2
- 239000001524 citrus aurantium oil Substances 0.000 claims description 2
- 239000010633 clary sage oil Substances 0.000 claims description 2
- 235000019864 coconut oil Nutrition 0.000 claims description 2
- 239000003240 coconut oil Substances 0.000 claims description 2
- 239000001555 commiphora myrrha gum extract Substances 0.000 claims description 2
- 239000001072 coriandrum sativum l. fruit oil Substances 0.000 claims description 2
- 235000005687 corn oil Nutrition 0.000 claims description 2
- 239000002285 corn oil Substances 0.000 claims description 2
- 239000001939 cymbopogon martini roxb. stapf. oil Substances 0.000 claims description 2
- 239000001224 daucus carota l. seed absolute Substances 0.000 claims description 2
- 229960000735 docosanol Drugs 0.000 claims description 2
- 229960002030 edoxudine Drugs 0.000 claims description 2
- XACKNLSZYYIACO-DJLDLDEBSA-N edoxudine Chemical compound O=C1NC(=O)C(CC)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XACKNLSZYYIACO-DJLDLDEBSA-N 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- ZDKZHVNKFOXMND-UHFFFAOYSA-N epinepetalactone Chemical compound O=C1OC=C(C)C2C1C(C)CC2 ZDKZHVNKFOXMND-UHFFFAOYSA-N 0.000 claims description 2
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 claims description 2
- 239000001902 eugenia caryophyllata l. bud oil Substances 0.000 claims description 2
- 235000008524 evening primrose extract Nutrition 0.000 claims description 2
- 239000010475 evening primrose oil Substances 0.000 claims description 2
- 229940089020 evening primrose oil Drugs 0.000 claims description 2
- 229960004396 famciclovir Drugs 0.000 claims description 2
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 claims description 2
- 239000010643 fennel seed oil Substances 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 229960002963 ganciclovir Drugs 0.000 claims description 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000010649 ginger oil Substances 0.000 claims description 2
- 239000010651 grapefruit oil Substances 0.000 claims description 2
- 239000008169 grapeseed oil Substances 0.000 claims description 2
- 239000010468 hazelnut oil Substances 0.000 claims description 2
- 239000010653 helichrysum oil Substances 0.000 claims description 2
- 239000010460 hemp oil Substances 0.000 claims description 2
- 239000001735 hyssopus officinalis l. herb oil Substances 0.000 claims description 2
- 229960000374 ibacitabine Drugs 0.000 claims description 2
- WEVJJMPVVFNAHZ-RRKCRQDMSA-N ibacitabine Chemical compound C1=C(I)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 WEVJJMPVVFNAHZ-RRKCRQDMSA-N 0.000 claims description 2
- 229960004716 idoxuridine Drugs 0.000 claims description 2
- 229960002751 imiquimod Drugs 0.000 claims description 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims description 2
- 229960003786 inosine Drugs 0.000 claims description 2
- 229940119170 jojoba wax Drugs 0.000 claims description 2
- 239000001851 juniperus communis l. berry oil Substances 0.000 claims description 2
- 239000001469 lavandula hydrida abrial herb oil Substances 0.000 claims description 2
- 239000010501 lemon oil Substances 0.000 claims description 2
- 239000000865 liniment Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 235000010335 lysozyme Nutrition 0.000 claims description 2
- 239000001780 majorana hortensis moench (origanum majorana l.) Substances 0.000 claims description 2
- 239000001683 mentha spicata herb oil Substances 0.000 claims description 2
- 229940051921 muramidase Drugs 0.000 claims description 2
- 235000019720 niaouli oil Nutrition 0.000 claims description 2
- 235000019488 nut oil Nutrition 0.000 claims description 2
- 235000008390 olive oil Nutrition 0.000 claims description 2
- 239000004006 olive oil Substances 0.000 claims description 2
- 239000010661 oregano oil Substances 0.000 claims description 2
- 229940111617 oregano oil Drugs 0.000 claims description 2
- 235000019161 pantothenic acid Nutrition 0.000 claims description 2
- 239000011713 pantothenic acid Substances 0.000 claims description 2
- 229940055726 pantothenic acid Drugs 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 239000000312 peanut oil Substances 0.000 claims description 2
- 229960001237 podophyllotoxin Drugs 0.000 claims description 2
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 claims description 2
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 claims description 2
- 239000001738 pogostemon cablin oil Substances 0.000 claims description 2
- 239000010667 rosehip oil Substances 0.000 claims description 2
- 239000010669 rosewood oil Substances 0.000 claims description 2
- 235000005713 safflower oil Nutrition 0.000 claims description 2
- 239000003813 safflower oil Substances 0.000 claims description 2
- 239000010670 sage oil Substances 0.000 claims description 2
- 239000010671 sandalwood oil Substances 0.000 claims description 2
- 235000011803 sesame oil Nutrition 0.000 claims description 2
- 239000008159 sesame oil Substances 0.000 claims description 2
- 229960000522 sinecatechins Drugs 0.000 claims description 2
- 235000019721 spearmint oil Nutrition 0.000 claims description 2
- 229940087124 spike lavender oil Drugs 0.000 claims description 2
- 239000010675 spruce oil Substances 0.000 claims description 2
- 239000002600 sunflower oil Substances 0.000 claims description 2
- 239000010677 tea tree oil Substances 0.000 claims description 2
- 229940111630 tea tree oil Drugs 0.000 claims description 2
- 229960000832 tromantadine Drugs 0.000 claims description 2
- UXQDWARBDDDTKG-UHFFFAOYSA-N tromantadine Chemical compound C1C(C2)CC3CC2CC1(NC(=O)COCCN(C)C)C3 UXQDWARBDDDTKG-UHFFFAOYSA-N 0.000 claims description 2
- 229940093257 valacyclovir Drugs 0.000 claims description 2
- 239000001238 valeriana officinalis l. root oil Substances 0.000 claims description 2
- 239000010679 vetiver oil Substances 0.000 claims description 2
- 239000008170 walnut oil Substances 0.000 claims description 2
- 239000010497 wheat germ oil Substances 0.000 claims description 2
- 239000009637 wintergreen oil Substances 0.000 claims description 2
- 230000003602 anti-herpes Effects 0.000 abstract description 4
- 210000003491 skin Anatomy 0.000 description 17
- 206010067152 Oral herpes Diseases 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 230000003902 lesion Effects 0.000 description 10
- 239000003443 antiviral agent Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000011282 treatment Methods 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 7
- 230000035515 penetration Effects 0.000 description 7
- 230000035876 healing Effects 0.000 description 5
- 208000003251 Pruritus Diseases 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 208000009889 Herpes Simplex Diseases 0.000 description 3
- 239000004909 Moisturizer Substances 0.000 description 3
- 229940121357 antivirals Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 230000001333 moisturizer Effects 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000037048 Prodromal Symptoms Diseases 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 229940010726 acyclovir topical cream Drugs 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940124977 antiviral medication Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229940008848 penciclovir topical cream Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000036572 transepidermal water loss Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
- SFAAOBGYWOUHLU-UHFFFAOYSA-N 2-ethylhexyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC SFAAOBGYWOUHLU-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-SSDOTTSWSA-N 3-[[(2s)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]propanoic acid Chemical class OCC(C)(C)[C@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-SSDOTTSWSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 125000005274 4-hydroxybenzoic acid group Chemical group 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- ZDQWESQEGGJUCH-UHFFFAOYSA-N Diisopropyl adipate Chemical compound CC(C)OC(=O)CCCCC(=O)OC(C)C ZDQWESQEGGJUCH-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010066888 Herpes pharyngitis Diseases 0.000 description 1
- 206010019973 Herpes virus infection Diseases 0.000 description 1
- 208000000440 Herpetic Stomatitis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 description 1
- 231100000087 Toxic epidermal necrolysis Toxicity 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229940010729 allantoin topical cream Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940124397 anti-herpes virus drug Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229960002645 boric acid Drugs 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 229940075882 denavir Drugs 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 229940010155 dexpanthenol topical cream Drugs 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940078545 isocetyl stearate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940056211 paraffin Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000002212 purine nucleoside Substances 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000000427 trigeminal ganglion Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002568 urticarial effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 229940107931 zovirax Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Definitions
- the present invention relates to a topical composition
- a topical composition comprising an antiviral active ingredient or analogues or derivatives thereof which is enhanced with antiherpes oils in a combination with an acid active ingredient or analogues or derivatives thereof which is enhanced with oils.
- Herpes simplex Virus 1 and 2 are very large viruses with very similar characteristics. Almost any human cell type can be infected by HSV. In many cells, such as endothelial cells and fibroblasts, infection is lytic but neurones normally support a latent infection. The hallmark of herpes infection is the ability to infect epithelial mucosal cells or lymphocytes. A reddened area gives rise to a macule which crusts to form a papule. The fluid in this blister is full of virus. As long as the virus is kept moist it can remain infectious Herpes simplex 1 and 2 can infect both humans and other animals but only humans show symptoms of disease.
- Oral herpesis usually caused by HSV-I, but rarely can be caused by HSV-2.
- primary herpetic gingivostomatitis the typical clear lesions first develop followed by ulcers that have a white appearance.
- the infection often initially on the lips can spread to all parts of the mouth and pharynx. Reactivation from the trigeminal ganglia can result in what are known as cold sores.
- Herpes pharyngitis is often associated with other viral infections of the upper respiratory tract. The disease is more severe in immunosuppressed people such as AIDS patients.
- Herpes Labialis also known as cold sores, is characterized by a high rate of recurrences, most often at the site of initial infection (recurrent Herpes Labialis).
- the global sero-prevalence of HSV-I in adults is currently 70-80%, which results in 400 million or more cold sores annually.
- Approximately 40% of the infected population has had a cold sore at one time or another and most people who have had cold sores will have recurrent outbreaks. Over 50 million adults in the United States have 2 or more outbreaks per year.
- Herpes Labialis is a benign disease that regresses spontaneously, it is highly contagious with high viral titers in blisters and effluent. Herpes Labialis causes physical pain and can also be disfiguring especially in those patients with frequent recurrences.
- Antiviral drugs are a class of medication used specifically for treating viral infections. Like antibiotics for bacteria, specific antivirals are used for specific viruses. Unlike most antibiotics, antiviral drugs do not destroy their target pathogen; instead they inhibit their development. Antiviral drugs are one class of antimicrobials, a larger group which also includes antibiotic (also termed antibacterial), antifungal and antiparasitic drugs, or antiviral drugs based on monoclonal antibodies. Most antivirals are considered relatively harmless to the host, and therefore can be used to treat infections. They should be distinguished from viricides, which are not medication but deactivate or destroy virus particles, either inside or outside the body.
- acyclovir shown as Formula I
- ointment brand name Zovirax®
- penciclovir shown as Formula II cream
- Denavir® brand name Denavir®
- These topical drugs are put directly on the lesions themselves, but can also be used at the onset of prodrome.
- Other topical treatments for oral herpes are available over-the-counter (OTC), but are not antiviral compounds like acyclovir and penciclovir.
- acyclovir and penciclovir topical cream is commonly associated (>1 % of patients) with: dry or flaking skin or transient stinging/burning sensations.
- Infrequent adverse effects include erythema or itch. (Rossi, S, ed. (2013). Australian Medicines Handbook (2013). Sydney: The Australian Medicines Handbook Unit Trust. ISBN 978-0- 9805790-9-3)
- adverse effects or events associated with antiviral drugs include rash, pruritus, toxic epidermal necrolysis, urticarial.
- Acyclovir and penciclovir also suffers from the disadvantage that it has a low solubility in water and is almost totally insoluble in hydrophobic solvent systems.
- any formulation of a pharmaceutically active compound should be stable for long periods of time, should not lose its potency, should not discolor or form insoluble substances or complexes, and should not be unduly irritating to the skin or mucosa.
- topical formulation also satisfy the criteria of adequate stability, maintenance of potency and are not unduly irritating to the skin or mucosa and have the advantages over the prior art formulation of penetrating skin more effectively and in greater concentration with the result that a rapid, complete cure of the infection is achieved. Description of the invention
- the present invention relates to a topical pharmaceutical composition
- a topical pharmaceutical composition comprising an antiviral active ingredient or analogues or derivatives thereof in a combination with an acid active ingredient or analogues or derivatives thereof.
- the present invention relates to a topical composition
- a topical composition comprising an antiviral active ingredient or analogues or derivatives thereof which is enhanced with antiherpes oils in a combination with an acid active ingredient or analogues or derivatives thereof which is enhanced with oils.
- an antiviral active ingredient is selected from the group consisting of acyclovir, valacyclovir, famciclovir, ganciclovir, penciclovir, docosanol, edoxudine, ibacitabine, idoxuridine, imiquimod, inosine, muramidase, podophyllotoxin, sinecatechins or tromantadine or analogues or derivatives thereof.
- an antiviral active ingredient is preferably guanosine analogue of antiviral active ingredient.
- Guanosine is a purine nucleoside.
- Nucleoside and nucleotide analogues can be used in therapeutic drugs, include a range of antiviral products used to prevent viral replication in infected cells.
- an antiviral active ingredient is preferably acyclovir or penciclovir.
- Acyclovir is a guanosine analogue antiviral medication. It is primarily used for the treatment of herpes simplex virus infections. The chemical name is acycloguanosine (ACV).
- Penciclovir is a guanosine analogue antiviral drug used for the treatment of various herpesvirus infections. It is a nucleoside analogue which exhibits low toxicity and good selectivity. Because penciclovir is absorbed poorly when given orally (by mouth) it is used as a topical treatment.
- an acid active ingredient is selected from the group consisting of glyoxylic acid, uric acid or pantothenic acid or analogues or derivatives thereof.
- Dexpanthenol is an alcoholic analogue of D-pantothenic acid and cholinergic agent. Allantoin is is a diureide of glyoxylic acid and it is a product of oxidation of uric acid by purine catabolism.
- an acid active ingredient is preferably panthenol, dexpanthenol or allantoin.
- allantoin has several beneficial effects including: a moisturizing and keratolytic effect, increasing the water content of the extracellular matrix and enhancing the desquamation of upper layers of dead skin cells, increasing the smoothness of the skin; promoting cell proliferation and wound healing; and a soothing, anti-irritant, and skin protectant effect by forming complexes with irritant and sensitizing agents. Allantoin ameliorates the wound healing process, by modulating the inflammatory response. Allantoin also promotes fibroblast proliferation and synthesis of the extracellular matrix.
- the topical pharmaceutical composition comprising acyclovir in a combination with an acid active ingredient or analogues or derivatives thereof.
- the topical pharmaceutical composition comprising acyclovir in a combination with an acid active ingredient or analogues or derivatives thereof wherein acyclovir is present in an amount of 1 .0 to 10.0% by weight of total formulation.
- the topical pharmaceutical composition comprising an antiviral active ingredient or analogues or derivatives thereof in a combination with allantoin.
- the topical pharmaceutical composition comprising an antiviral active ingredient or analogues or derivatives thereof in a combination with allantoin, wherein allantoin is present in an amount of 0.1 to 5.0% by weight of total formulation.
- the topical pharmaceutical composition comprising acyclovir in a combination with allantoin.
- the topical pharmaceutical composition comprising acyclovir is present in an amount of 1 .0 to 10.0% and allantoin is present in an amount of 0.1 to 5.0% by weight of total formulation.
- panthenol or dexpanthenol is based on good skin penetration and high local concentrations of dexpanthenol when administered in an adequate vehicle.
- Topical dexpanthenol acts like a moisturizer, improving stratum corneum hydration, reducing transepidermal water loss and maintaining skin softness and elasticity. It activates of fibroblast proliferation, which is of relevance in wound healing.
- the stimulation of epithelization, granulation and mitigation of itching were the most prominent effects of formulations containing dexpanthenol.
- the topical administration of dexpanthenol preparations is well tolerated, with minimal risk of skin irritancy or sensitization.
- the topical pharmaceutical composition comprising penciclovir in a combination with an acid active ingredient or analogues or derivatives thereof.
- the topical pharmaceutical composition comprising penciclovir in a combination with an acid active ingredient or analogues or derivatives thereof wherein penciclovir is present in an amount of 0.1 to 5.0% by weight of total formulation.
- the topical pharmaceutical composition comprising an antiviral active ingredient or analogues or derivatives thereof in a combination with dexpanthenol or panthenol.
- the topical pharmaceutical composition comprising an antiviral active ingredient or analogues or derivatives thereof in a combination with dexpanthenol or panthenol wherein dexpanthenol or panthenol is present in an amount of 1 .0 to 10.0% by weight of total formulation.
- the topical pharmaceutical composition comprising penciclovir in a combination with dexpanthenol or panthenol.
- the topical pharmaceutical composition penciclovir is present in an amount of 0.1 to 5.0% and dexpanthenol is present in an amount of 1 .0 to 10.0% by weight of total formulation.
- panthenol or dexpanthenol it has been found that by using this specific concentration of panthenol or dexpanthenol, an increased concentration of solubilised penciclovir can be attained, leading to enhanced activity and efficacy of the formulation. It provides rapid penetration with minimized skin irritation.
- compositions further comprise at least one pharmaceutically acceptable excipient.
- one or more pharmaceutically acceptable excipient is selected from the group consisting of oils, lipophilic substances, antimicrobial preservatives, water or the mixtures thereof.
- the oil is selected from the group consisting of almond oil, anise oil, avocado oil, babassu oil, basil oil, bay laurel oil, bergamot oil, black, pepper oil, bulgarian lavender oil, cajeput oil, calendula oil, camellia oil, canola oil, cardamom oil, carrot seed oil, caster oil, catnip oil, chamomile oil, cinnamon leaf oil, citronella oil, clary sage oil, clove bud oil, clove blossom oil, coconut oil, coriander seed oil, corn oil, eucalyptus oil, evening primrose oil, fir needle oil, frankincense oil, geranium oil, german blue chamomile oil, ginger oil, grapefruit oil, grapeseed oil, hazelnut oil, helichrysum oil, hemp seed oil,
- the oils are preferably geranium oil, lavender oil, melissa officinalis oil, peppermint oil, rosemary oil or mixtures thereof.
- the preferred composition comprises acyclovir, allantoin, geranium oil, lavender oil, melissa officinalis oil, peppermint oil, rosemary oil or mixtures thereof.
- compositions comprises penciclovir, dexpanthenol or panthenol, geranium oil, lavender oil, melissa officinalis oil, peppermint oil, rosemary oil or mixtures thereof.
- oil is present in an amount of 0.001 % to 0.5 by weight of total formulation.
- acyclovir or penciclovir with oils, preferably melissa officinalis oil, peppermint oil, rosemary oil or mixtures can treat active herpes viral infections.
- oils preferably melissa officinalis oil, peppermint oil, rosemary oil or mixtures.
- the novel formulation can decrease the time of healing, decrease the frequency of recurrent lesions, and can prevent lesion formation when prodromal symptoms are noted. It has further been found that this combination even effective in the treatment of lesions resistant to high dose antivirals.
- melissa officinalis oil is present in an amount of 0.001 % to 0.1 % by weight of total formulation.
- peppermint oil is present in an amount of 0.001 % to 0.1 % by weight of total formulation.
- rosemary oil is present in an amount of 0.001 % to 0.1 % by weight of total formulation.
- geranium oil and lavender oil or mixtures are well-known for positive effects on various skin disorders like rashes, dermatitis, eczema, infections and scars, etc. It has been found that the combined use of acyclovir or penciclovir with oils, preferably geranium oil, lavender oil or mixtures can help sore fade away, make skin flawless and enhance moisturizer, improving stratum corneum hydration, reducing transepidermal water loss and maintaining skin softness and elasticity activities of allantoin and panthenol or dexpanthenol.
- geranium oil is present in an amount of 0.001 % to 0.1 % by weight of total formulation.
- lavender oil is present in an amount of 0.001 % to 0.1 % by weight of total formulation.
- the ratio of oil to acyclovir is between 0.0001 - 0.5 (w/w).
- the ratio of oil to penciclovir is between 0.0002 - 5 (w/w).
- the lipophilic substance is selected from the group consisting of beeswax, capric acid, caprylic acid, silicone oil, white soft paraffin, liquid paraffin, di- isopropyladipate, isocetyl stearate, macrogol cetostearyl ether, diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, sorbitan stearate, 2- ethylhexyl palmitate, cetyl alcohol, stearyl alcohol or mixtures thereof.
- the lipophilic substance are preferably white soft paraffin, liquid paraffin, macrogol cetostearyl ether, sorbitan stearate, cetyl alcohol, stearyl alcohol or mixtures thereof.
- the selected lipophilic substances are important to achieve a rapid transdermal penetration of the active ingredient.
- macrogol cetostearyl ether is present in an amount of 1 .0% to 10.0% by weight of total formulation.
- cetyl alcohol is present in an amount of 1 .0% to 10.0% by weight of total formulation.
- stearyl alcohol is present in an amount of 1 .0% to 10.0% by weight of total formulation.
- liquid paraffin is present in an amount of 1 .0% to 10.0% by weight of total formulation.
- white soft paraffin is present in an amount of 1 .0% to 10.0% by weight of total formulation.
- sorbitan stearate is present in an amount of 1 .0% to 10.0% by weight of total formulation.
- the antimicrobial preservative is selected from the group consisting of propylene glycol, phenoxyethanol, methyl paraben, propyl paraben and their salts (such as sodium, potassium), sodium benzoate, citric acid, benzoic acid, butylated hydroxytoluene, boric acid, sorbic acid, benzyl alcohol, benzalconium chloride, parahydroxybenzoic acids or butylated hydroxyanisole or mixtures thereof.
- the antimicrobial preservatives are preferably propylene glycol, phenoxyethanol or mixtures thereof.
- said topical pharmaceutical composition applied in the form of foam, cream, gel, paste, lotion, emulsion, balm or combinations thereof.
- said topical pharmaceutical composition preferably applied in the form of cream.
- the topical pharmaceutical composition is for use in treating a herpes virus infection, preventing a herpes virus infection, preventing recurrent herpes virus infection, preventing reactivation of a herpes virus, minimizing reactivation of a herpes virus.
- said herpes viral infection is cold sore.
- the herpes virus infection is caused by a herpes virus selected from the group consisting of Herpes Simplex Virus Type 1 (HSV-I), Herpes Simplex Virus Type 2 (HSV-2), Varicella Zoster Virus (VZV), Epstein-Bar Virus (EBV), Cytomegalovirus (CMV), Herpes Lymphotropic Virus, Human Herpes Virus Type 7 (HHV- 7), Human Herpes Virus Type 8 (HHV-8).
- HSV-I Herpes Simplex Virus Type 1
- HSV-2 Herpes Simplex Virus Type 2
- VZV Varicella Zoster Virus
- EBV Epstein-Bar Virus
- CMV Cytomegalovirus
- HHV- 7 Human Herpes Virus Type 7
- HHV-8 Human Herpes Virus Type 8
- the topical pharmaceutical composition comprising; a. 1 .0 to 10.0% acyclovir by weight of total formulation, preferably 4.0 to 6.0% acyclovir by weight of total formulation b. 0.1 to 5.0% allantoin by weight of total formulation, preferably 0.1 to 2.0% allantoin by weight of total formulation c. 0.001 % to 0.1 % peppermint oil by weight of total formulation, preferably 0.005 to 0.05% peppermint oil by weight of total formulation d. 0.001 % to 0.1 % melissa officinalis oil by weight of total formulation, preferably 0.01 to 0.05% melissa officinalis oil by weight of total formulation e.
- 0.001 % to 0.1 % rosemary oil by weight of total formulation preferably 0.01 % to 0.1 % rosemary oil by weight of total formulation f. 0.001 % to 0.1 % geranium oil by weight of total formulation, preferably 0.005% to 0.05% geranium oil by weight of total formulation g. 0.001 % to 0.1 % lavender oil by weight of total formulation, preferably 0.01 % to 0.1 % lavender oil by weight of total formulation
- the topical pharmaceutical composition consisting of; a. 1 .0 to 10.0% acyclovir by weight of total formulation, preferably 4.0 to 6.0% acyclovir by weight of total formulation b. 0.1 to 5.0% allantoin by weight of total formulation, preferably 0.1 to 2.0% allantoin by weight of total formulation c. 0.001 % to 0.1 % peppermint oil by weight of total formulation, preferably 0.005 to 0.05% peppermint oil by weight of total formulation d. 0.001 % to 0.1 % melissa officinalis oil by weight of total formulation, preferably 0.01 to 0.05% melissa officinalis oil by weight of total formulation e.
- 0.001 % to 0.1 % rosemary oil by weight of total formulation preferably 0.01 % to 0.1 % rosemary oil by weight of total formulation f. 0.001 % to 0.1 % geranium oil by weight of total formulation, preferably 0.005% to 0.05% geranium oil by weight of total formulation g. 0.001 % to 0.1 % lavender oil by weight of total formulation, preferably 0.01 % to 0.1 % lavender oil by weight of total formulation h. 1 .0% to 10.0% macrogol cetostearyl ether by weight of total formulation, preferably 4.0 to 6.0% macrogol cetostearyl ether by weight of total formulation i.
- the topical pharmaceutical composition comprising; a.
- penciclovir by weight of total formulation preferably 0.5 to 3.0% penciclovir by weight of total formulation b. 1 .0 to 10.0% dexpanthenol by weight of total formulation, preferably 2.0 to 5.0% dexpanthenol by weight of total formulation c. 0.001 % to 0.1 % peppermint oil by weight of total formulation, preferably 0.005 to 0.05% peppermint oil by weight of total formulation d. 0.001 % to 0.1 % melissa officinalis oil by weight of total formulation, preferably 0.01 to 0.05% melissa officinalis oil by weight of total formulation e.
- 0.001 % to 0.1 % rosemary oil by weight of total formulation preferably 0.01 % to 0.1 % rosemary oil by weight of total formulation f. 0.001 % to 0.1 % geranium oil by weight of total formulation, preferably 0.005% to 0.05% geranium oil by weight of total formulation g. 0.001 % to 0.1 % lavender oil by weight of total formulation, preferably 0.01 % to 0.1 % lavender oil by weight of total formulation
- the topical pharmaceutical composition consisting of; a. 0.1 to 5.0% penciclovir by weight of total formulation, preferably 0.5 to 3.0% penciclovir by weight of total formulation b. 1 .0 to 10.0% dexpanthenol by weight of total formulation, preferably 2.0 to 5.0% dexpanthenol by weight of total formulation c. 0.001 % to 0.1 % peppermint oil by weight of total formulation, preferably 0.005 to 0.05% peppermint oil by weight of total formulation d. 0.001 % to 0.1 % melissa officinalis oil by weight of total formulation, preferably 0.01 to 0.05% melissa officinalis oil by weight of total formulation e.
- 0.001 % to 0.1 % rosemary oil by weight of total formulation preferably 0.01 % to 0.1 % rosemary oil by weight of total formulation f. 0.001 % to 0.1 % geranium oil by weight of total formulation, preferably 0.005% to 0.05% geranium oil by weight of total formulation g. 0.001 % to 0.1 % lavender oil by weight of total formulation, preferably 0.01 % to 0.1 % lavender oil by weight of total formulation h. 1 .0% to 10.0% macrogol cetostearyl ether by weight of total formulation, preferably 4.0 to 6.0% macrogol cetostearyl ether by weight of total formulation i.
- I. 1 .0% to 10.0% white soft paraffin by weight of total formulation preferably 5.0% to 9.0% white soft paraffin by weight of total formulation m. 1 .0% to 10.0% sorbitan stearate by weight of total formulation, preferably 2.0% to 5.0% sorbitan stearate by weight of total formulation n. 1 .0% to 10.0% propylene glycol by weight of total formulation, preferably 2.0% to 5.0% propylene glycol by weight of total formulation o. 0.1 % to 10.0% phenoxyethanol by weight of total formulation, preferably 0.5% to 3.0% phenoxyethanol by weight of total formulation p. q.s. water
- the topical formulations of the present invention is used as an antiviral treatment especially for cold sore with the advantage of moisturizer to treat or prevent skin from irritation during the therapy.
- Acyclovir and penciclovir display antiviral activity and melissa officinalis oil, peppermint oil, rosemary oil or mixtures enhance antiviral activity.
- Panthenol dexpanthenol or allantoin soften and moisturize the skin and decrease itching and flaking and geranium oil and lavender oil or mixtures enhance this activity.
- Mixture 1 is homogenized with melted mixture 2. This mixture is transferred to a beaker with heated to 80 Q C water and homogenized in a homogeniser.
- Penciclovir and dexpanthenol, oils, propylene glycol, liquid paraffin, phenoxyethanol are mixed and heated to 75 Q C (mixture 1 ).
- Mixture 1 is homogenized with melted mixture 2. This mixture is transferred to a beaker with heated to 80 Q C water and homogenized in a homogeniser.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne une composition topique comprenant un principe actif antiviral ou des analogues ou dérivés de ce dernier, qui est enrichi en huiles contre l'herpès en combinaison avec un principe actif acide ou des analogues ou dérivés de ce dernier qui est enrichi en huiles.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16759693.1A EP3337512A1 (fr) | 2015-08-17 | 2016-08-16 | Composition antivirale topique |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2015/10146 | 2015-08-17 | ||
TR201510146 | 2015-08-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017029298A1 true WO2017029298A1 (fr) | 2017-02-23 |
Family
ID=56852229
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2016/069450 WO2017029298A1 (fr) | 2015-08-17 | 2016-08-16 | Composition antivirale topique |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP3337512A1 (fr) |
WO (1) | WO2017029298A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112514926A (zh) * | 2020-12-14 | 2021-03-19 | 杭州象外环保科技有限公司 | 一种灭活冠状病毒的天然植萃精油消毒剂及应用 |
CN112616861A (zh) * | 2020-12-14 | 2021-04-09 | 杭州象外环保科技有限公司 | 一种天然植萃精油新型冠状病毒消毒剂及其应用 |
WO2023062348A1 (fr) | 2021-10-13 | 2023-04-20 | Reckitt Benckiser Health Limited | Compositions antivirales et leurs procédés de production et d'utilisation |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4199574A (en) | 1974-09-02 | 1980-04-22 | Burroughs Wellcome Co. | Methods and compositions for treating viral infections and guanine acyclic nucleosides |
EP0044543B1 (fr) | 1980-07-18 | 1984-06-06 | The Wellcome Foundation Limited | Formulations topiques à base de 9(2-hydroxyéthoxyméthyl) guanine |
WO1987005604A1 (fr) | 1984-09-20 | 1987-09-24 | Beecham Group P.L.C. | Derives de 2-aminopurine et procede de preparation desdits derives |
WO1991011187A1 (fr) | 1990-01-26 | 1991-08-08 | Beecham Group Plc | Preparation pharmaceutique |
WO1998017264A1 (fr) * | 1996-10-24 | 1998-04-30 | Nextech Enterprises International | Composition et procede de traitement topique des infections a herpesvirus actives |
US5869529A (en) * | 1994-07-20 | 1999-02-09 | Agis Industries (1983) Ltd. | Topical preparation for the prevention and treatment of lesions and sores associated with a herpes virus |
WO2009115510A1 (fr) * | 2008-03-17 | 2009-09-24 | Medivir Ab | Formulation antivirale |
WO2013046161A1 (fr) * | 2011-09-28 | 2013-04-04 | Fidia Farmaceutici S.P.A. | Compositions pharmaceutiques topiques comprenant de l'acyclovir |
WO2014131096A1 (fr) * | 2013-02-27 | 2014-09-04 | Advance Pharma Tecnologia E Inovação Ltda - Me | Formulation obtenue par association de l'antiviral aciclovir avec la vitamine b6 et un anti-histaminique pour le traitement de l'herpès et moyen d'application |
-
2016
- 2016-08-16 WO PCT/EP2016/069450 patent/WO2017029298A1/fr active Application Filing
- 2016-08-16 EP EP16759693.1A patent/EP3337512A1/fr not_active Withdrawn
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4199574A (en) | 1974-09-02 | 1980-04-22 | Burroughs Wellcome Co. | Methods and compositions for treating viral infections and guanine acyclic nucleosides |
EP0044543B1 (fr) | 1980-07-18 | 1984-06-06 | The Wellcome Foundation Limited | Formulations topiques à base de 9(2-hydroxyéthoxyméthyl) guanine |
WO1987005604A1 (fr) | 1984-09-20 | 1987-09-24 | Beecham Group P.L.C. | Derives de 2-aminopurine et procede de preparation desdits derives |
WO1991011187A1 (fr) | 1990-01-26 | 1991-08-08 | Beecham Group Plc | Preparation pharmaceutique |
US5869529A (en) * | 1994-07-20 | 1999-02-09 | Agis Industries (1983) Ltd. | Topical preparation for the prevention and treatment of lesions and sores associated with a herpes virus |
WO1998017264A1 (fr) * | 1996-10-24 | 1998-04-30 | Nextech Enterprises International | Composition et procede de traitement topique des infections a herpesvirus actives |
WO2009115510A1 (fr) * | 2008-03-17 | 2009-09-24 | Medivir Ab | Formulation antivirale |
WO2013046161A1 (fr) * | 2011-09-28 | 2013-04-04 | Fidia Farmaceutici S.P.A. | Compositions pharmaceutiques topiques comprenant de l'acyclovir |
WO2014131096A1 (fr) * | 2013-02-27 | 2014-09-04 | Advance Pharma Tecnologia E Inovação Ltda - Me | Formulation obtenue par association de l'antiviral aciclovir avec la vitamine b6 et un anti-histaminique pour le traitement de l'herpès et moyen d'application |
Non-Patent Citations (2)
Title |
---|
ADELAIDE: "The Australian Medicines Handbook Unit Trust" |
ROSSI, S,: "Australian Medicines Handbook", 2013 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112514926A (zh) * | 2020-12-14 | 2021-03-19 | 杭州象外环保科技有限公司 | 一种灭活冠状病毒的天然植萃精油消毒剂及应用 |
CN112616861A (zh) * | 2020-12-14 | 2021-04-09 | 杭州象外环保科技有限公司 | 一种天然植萃精油新型冠状病毒消毒剂及其应用 |
CN112514926B (zh) * | 2020-12-14 | 2021-10-01 | 杭州象外环保科技有限公司 | 一种灭活冠状病毒的天然植萃精油消毒剂及应用 |
CN112616861B (zh) * | 2020-12-14 | 2021-10-01 | 杭州象外环保科技有限公司 | 一种天然植萃精油新型冠状病毒消毒剂及其应用 |
WO2023062348A1 (fr) | 2021-10-13 | 2023-04-20 | Reckitt Benckiser Health Limited | Compositions antivirales et leurs procédés de production et d'utilisation |
Also Published As
Publication number | Publication date |
---|---|
EP3337512A1 (fr) | 2018-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2456356C (fr) | Composition topique pour soulager la douleur ou l'inflammation dues au virus de l'herpes | |
US4588744A (en) | Method of forming an aqueous solution of 3-3-Bis(p-hydroxyphenyl)-phthalide | |
AU2019203449B2 (en) | Topical diclofenac sodium compositions | |
KR20180053292A (ko) | 건선을 치료하기 위한 코르티코스테로이드 및 레티노이드를 포함하는 국소 조성물 | |
US20210169902A1 (en) | Use of oxygenated cholesterol sulfates (ocs) to treat inflammatory skin disease and skin lesions | |
JP6385938B2 (ja) | 外用ステロイド組成物および方法 | |
JP2014511341A (ja) | 皮膚状態を治療するための組成物 | |
CN114423412A (zh) | 包含***二酚的外用制剂、制备组合物的方法及其用途 | |
WO2017029298A1 (fr) | Composition antivirale topique | |
JP2015530380A (ja) | 乾癬を治療するための組成物 | |
WO1999012545A2 (fr) | Medicaments contenant acyclovir | |
MX2010010111A (es) | Formulacion topica de dosis fija estable. | |
JPH03204815A (ja) | 皮膚炎に対する治療用組成物 | |
US5036050A (en) | Compositions containing thymopentin for topical treatment of skin disorders | |
JPS6251617A (ja) | ビダラビンゲル軟膏 | |
JP4145493B2 (ja) | ジメチコンを含むアシクロビール組成物 | |
EP0416739A1 (fr) | Compositions pharmaceutiques à base de penciclovir | |
US7618950B2 (en) | Method for treatment and prevention of herpes zoster by topical application | |
EP0073758B1 (fr) | Traitement des infections virales inflammatoires, de l'acne, des dermatites et de l'arthrite | |
US20220040138A1 (en) | Teriflunomide topical pharmaceutical compositions | |
WO1997045123A1 (fr) | Formulations pharmaceutiques topiques comprenant de l'aciclovir | |
WO2021214789A1 (fr) | Nouvelles utilisations de l'aprémilast | |
JP2009542703A (ja) | ***ヘルペス(単純疱疹)の局所治療のための抗ウイルス組成物およびそれを用いる方法 | |
JP2002302433A (ja) | 低刺激性クリーム剤 | |
KR20150128952A (ko) | 플루니솔리드의 국소 조성물 및 치료 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16759693 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2016759693 Country of ref document: EP |